Compare Stocks: BFRI, ALDX, LONA, and ZYBT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALDX Aldeyra Therapeutics	$0.92 -3.3%	$1.40	$0.86 ▼ $5.93	$55.28M	1.21	1.88 million shs	698,974 shs
BFRI Biofrontera	$0.97 +5.6%	$1.30	$0.55 ▼ $1.66	$14.41M	0.86	605,178 shs	275,172 shs
LONA Athira Pharma	$5.75	$6.80	$2.21 ▼ $14.21	$54.01M	2.11	482,347 shs	66,684 shs
ZYBT Zhengye Biotechnology	$1.73 +50.4%	$1.54	$0.62 ▼ $8.01	$81.99M	-2.31	23,491 shs	29.56 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALDX Aldeyra Therapeutics	0.00%	-21.68%	-37.24%	-55.73%	-83.70%
BFRI Biofrontera	0.00%	-4.43%	-33.56%	-11.82%	-3.96%
LONA Athira Pharma	0.00%	+19.29%	-16.18%	-40.10%	+574,999,900.00%
ZYBT Zhengye Biotechnology	0.00%	+39.52%	+8.81%	+116.25%	-43.83%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALDX Aldeyra Therapeutics	$0.92 -3.3%	$1.40	$0.86 ▼ $5.93	$55.28M	1.21	1.88 million shs	698,974 shs
BFRI Biofrontera	$0.97 +5.6%	$1.30	$0.55 ▼ $1.66	$14.41M	0.86	605,178 shs	275,172 shs
LONA Athira Pharma	$5.75	$6.80	$2.21 ▼ $14.21	$54.01M	2.11	482,347 shs	66,684 shs
ZYBT Zhengye Biotechnology	$1.73 +50.4%	$1.54	$0.62 ▼ $8.01	$81.99M	-2.31	23,491 shs	29.56 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALDX Aldeyra Therapeutics	0.00%	-21.68%	-37.24%	-55.73%	-83.70%
BFRI Biofrontera	0.00%	-4.43%	-33.56%	-11.82%	-3.96%
LONA Athira Pharma	0.00%	+19.29%	-16.18%	-40.10%	+574,999,900.00%
ZYBT Zhengye Biotechnology	0.00%	+39.52%	+8.81%	+116.25%	-43.83%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALDX Aldeyra Therapeutics	2.00	Hold	$5.50	500.24% Upside
BFRI Biofrontera	2.00	Hold	N/A	N/A
LONA Athira Pharma	2.50	Moderate Buy	$17.33	201.45% Upside
ZYBT Zhengye Biotechnology	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest BFRI, ALDX, LONA, and ZYBT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/30/2026	ALDX Aldeyra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$2.00
9/29/2026	ALDX Aldeyra Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/14/2026	ALDX Aldeyra Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/31/2026	ALDX Aldeyra Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/19/2026	LONA Athira Pharma	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$16.00 ➝ $15.00
8/17/2026	ALDX Aldeyra Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/17/2026	LONA Athira Pharma	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Market Outperform	$18.00 ➝ $17.00
8/7/2026	LONA Athira Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/3/2026	BFRI Biofrontera	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/30/2026	LONA Athira Pharma	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$18.00
7/20/2026	ZYBT Zhengye Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Sell (D)

(Data available from 10/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	$0.74 per share	N/A
BFRI Biofrontera	$41.71M	0.35	N/A	N/A	$0.90 per share	1.08
LONA Athira Pharma	N/A	N/A	N/A	N/A	$2.98 per share	N/A
ZYBT Zhengye Biotechnology	$16.64M	4.93	N/A	N/A	$0.93 per share	1.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALDX Aldeyra Therapeutics	-$33.85M	-$0.39	N/A	N/A	N/A	N/A	-53.14%	-34.94%	11/4/2026 (Estimated)
BFRI Biofrontera	-$10.54M	-$0.45	N/A	N/A	N/A	-13.78%	-145.81%	-31.30%	11/11/2026 (Estimated)
LONA Athira Pharma	-$105.61M	-$4.21	N/A	N/A	N/A	N/A	-411.58%	-225.73%	N/A
ZYBT Zhengye Biotechnology	-$9.98M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest BFRI, ALDX, LONA, and ZYBT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	ALDX Aldeyra Therapeutics	-$0.11	N/A	N/A	N/A	$2.50 million	N/A
8/14/2026	Q2 2026	LONA Athira Pharma	-$0.60	-$0.80	-$0.20	-$0.80	N/A	N/A
8/13/2026	Q2 2026	BFRI Biofrontera	-$0.1050	-$0.05	+$0.0550	-$0.05	$9.50 million	$12.00 million
8/6/2026	Q2 2026	ALDX Aldeyra Therapeutics	-$0.0875	-$0.09	-$0.0025	-$0.09	$31.33 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	N/A
BFRI Biofrontera	N/A	N/A	N/A	N/A	N/A
LONA Athira Pharma	N/A	N/A	N/A	N/A	N/A
ZYBT Zhengye Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALDX Aldeyra Therapeutics	N/A	4.91	4.91
BFRI Biofrontera	0.78	1.18	1.08
LONA Athira Pharma	N/A	7.01	7.01
ZYBT Zhengye Biotechnology	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALDX Aldeyra Therapeutics	59.71%
BFRI Biofrontera	10.08%
LONA Athira Pharma	57.12%
ZYBT Zhengye Biotechnology	N/A

Insider Ownership

Company	Insider Ownership
ALDX Aldeyra Therapeutics	11.80%
BFRI Biofrontera	8.10%
LONA Athira Pharma	25.73%
ZYBT Zhengye Biotechnology	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALDX Aldeyra Therapeutics	6	60.33 million	53.21 million	Optionable
BFRI Biofrontera	94	14.85 million	13.65 million	No Data
LONA Athira Pharma	19	9.39 million	6.98 million	No Data
ZYBT Zhengye Biotechnology	269	47.39 million	N/A	N/A

BFRI, ALDX, LONA, and ZYBT Headlines

Recent News About These Companies

Zhengye Biotechnology (NASDAQ:ZYBT) Shares Up 4.5% - Here's Why

October 8 at 2:41 AM | americanbankingnews.com

Zhengye Biotechnology Holding Ltd (ZYBT)

August 28, 2026 | ru.investing.com

Zhengye Biotechnology Regains Nasdaq Minimum Bid Price Compliance

August 6, 2026 | tipranks.com

Why Zhengye Biotechnology Holding (ZYBT) Stock Is Up Today

August 5, 2026 | quiverquant.comQ

Zhengye Biotechnology Stock Short Interest Report | NASDAQ:ZYBT | Benzinga

July 23, 2026 | benzinga.com

Zhengye Biotechnology Addresses Unusual Nasdaq Trading Activity

July 21, 2026 | tipranks.com

Zhengye Biotechnology says no material events behind unusual trading activity (NASDAQ: ZYBT)

July 21, 2026 | msn.com

Zhengye Biotechnology Holding Limited Says It Is Unaware of Material Non-Public Information Amid Unusual Trading Activity

July 21, 2026 | quiverquant.comQ

Zhengye Biotechnology Holding Limited Comments on Unusual Trading Activity

July 21, 2026 | globenewswire.com

Why Zhengye Biotechnology Holding Limited (ZYBT) Stock Is Up Today

July 20, 2026 | quiverquant.comQ

Zhengye Biotechnology Holding Ltd. Class A

July 13, 2026 | cnn.com

Zhengye Biotechnology Faces Nasdaq Minimum Bid Price Deficiency After May 29 Notice

June 4, 2026 | tipranks.com

Zhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

June 4, 2026 | globenewswire.com

Zhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial Results

April 28, 2026 | prnewswire.com

Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure Effective April 7, 2026

April 6, 2026 | quiverquant.comQ

Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure

April 6, 2026 | globenewswire.com

Zhengye Biotechnology Holding Ltd ZYBT

March 28, 2026 | morningstar.comM

Zhengye Biotechnology Shareholders Approve Governance and Share Structure Changes at March 24 AGM

March 25, 2026 | tipranks.com

Zhengye Biotechnology Director Resigns, Nasdaq Independence Deficiency to Be Addressed at March AGM

February 23, 2026 | tipranks.com

Zhengye Biotechnology Holding Limited Issues 2026 Chairman’s Letter to Shareholders

February 11, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BFRI, ALDX, LONA, and ZYBT Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

$0.92 -0.03 (-3.31%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$0.91 0.00 (-0.47%)

As of 10/9/2026 07:34 PM Eastern

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Biofrontera NASDAQ:BFRI

$0.97 +0.05 (+5.57%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$0.97 0.00 (-0.31%)

As of 10/9/2026 07:14 PM Eastern

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Athira Pharma NASDAQ:LONA

$5.75 0.00 (0.00%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$5.74 0.00 (-0.09%)

As of 10/9/2026 07:30 PM Eastern

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

Zhengye Biotechnology NASDAQ:ZYBT

$1.73 +0.58 (+50.45%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.79 +0.06 (+3.24%)

As of 10/9/2026 08:00 PM Eastern

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BFRI, ALDX, LONA, and ZYBT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BFRI, ALDX, LONA, and ZYBT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BFRI, ALDX, LONA, and ZYBT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BFRI, ALDX, LONA, and ZYBT Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

Biofrontera NASDAQ:BFRI

Athira Pharma NASDAQ:LONA

Zhengye Biotechnology NASDAQ:ZYBT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BFRI, ALDX, LONA, and ZYBT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BFRI, ALDX, LONA, and ZYBT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BFRI, ALDX, LONA, and ZYBT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BFRI, ALDX, LONA, and ZYBT Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

Biofrontera NASDAQ:BFRI

Athira Pharma NASDAQ:LONA

Zhengye Biotechnology NASDAQ:ZYBT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools